ADAG: Adagene Inc Broker Consensus Forecast
Adagene (ADAG) utilizes AI to develop anti-cancer antibodies, protecting its innovations with SAFE-body patents and generating royalties from partners. This daily price chart on GURU.Markets, where the indicator stands at 8.24, links this potential to financial instability stemming from a lack of sales and capital expenditure. Meanwhile, a sufficient cash reserve mitigates risks as the company awaits the outcomes of its drug trials.
Analytical breakdowns for Adagene (ADAG)
- stock value and consensus price forecast:
- market capitalization information:
- business book valuation details:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Adagene|ADAG - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital adagene.com|ADAG - Company Aggregate Debts|Debts to Book Capitalization Adagene Corp|ADAG - Company Long-Term Debt|Company Short-Term Loans and Borrowings Adagene|Quick Liquidity Indicator adagene.com
- company profitability and valuation multiples indicators:
ADAG - Net Profit|Projected Future Earnings Adagene|ADAG - Price to Earnings Ratio|Future Price to Earnings Multiple adagene.com|ADAG - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Adagene Corp|ADAG - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Adagene|ADAG - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months adagene.com|ADAG - Net earnings per share growth this year|Earnings growth forecast for next year Adagene
General company analysis:ADAG Adagene Inc
This indicator aggregates expert expectations for the asset's fair value, reflecting the balance between the business's fundamental potential and current macroeconomic risks. The trend in the consensus target price discounts the issuer's solvency, which for Adagene (ADAG) signifies an assessment of the success of antibody development within a sovereign cycle protected by strategic partnerships with global pharma behemoths.
Competitors of Adagene
Analyst Consensus Forecast argenx.com (ARGX)|Analyst Consensus Forecast BNTX (BioNTech)|ABVX: Broker Consensus Forecast|ADMA Bio - Analyst Consensus Forecast|PTGX - Analyst Consensus Forecast|IMVT: Analyst Consensus Forecast|Analyst Target Range kiniksa.com KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|KYTX: Analyst Consensus Forecast|Broker Consensus Forecast TLSA|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Ventyx Biosciences Inc.|Analyst Consensus Forecast THTX|Avalo Therapeutics Inc (AVTX) - Analyst Target Range|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|agenusbio.com (AGEN) - Average Forecast Price|CLYM - Price Target Chart|ZURA (zurabio.com) - Broker Consensus Forecast|ATYR: Analyst Consensus Forecast|Average Forecast Price Ikena Oncology (IMA)|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|Analyst Consensus Forecast Equillium Bio|Analyst Consensus Forecast CNTB|immunic-therapeutics.com - Broker Consensus Forecast|Analyst Consensus Forecast ATRA (Atara Bio)|Analyst Consensus Forecast InflaRx NV IFRX|X4 Pharmaceuticals - Analyst Consensus Forecast|Analyst Target Range Adicet Bio (ACET)|celularity.com (CELU) - Price Target Chart|Forecast Levels Chart INMB (INmune Bio Inc)|BRNS (Barinthus Bio) - Analyst Consensus Forecast|KZR: Fair Value Consensus|Analyst Consensus Forecast SABS|Analyst Consensus Forecast akaritx.com (AKTX)|Price Target Chart Enlivex Therapeutics Ltd. ENLV|Fair Value Consensus QTTB|GOVX - Price Target Chart|Edesa Biotech Corp (EDSA) - Consensus Target|IBIO: Analyst Consensus Forecast|Carisma Therapeutics Inc. (CARM) - Analyst Consensus Forecast|Consensus Target XTLB|BOLT: Fair Value Consensus|Analyst Consensus Forecast HCWB|Analyst Median Target aptevotherapeutics.com|Price Target Chart AIM ImmunoTech AIM|ADTX - Consensus Target|GRI - Price Target Chart|XORTX Therapeutics Inc (XRTX) - Consensus Target|HIND (ReShape Lifesciences) - Consensus Target|Revelation Biosciences Corp (REVB) - Analyst Consensus Forecast|Price Target Chart Indaptus Therapeutics|Broker Consensus Forecast SCNI (scinai.com)|Analyst Consensus Forecast CALI|AFMD - Average Forecast Price|Analyst Consensus Forecast ALLK (Allakos)|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGM Bio - Analyst Consensus Forecast|ITOS (iteostherapeutics.com) - Broker Consensus Forecast|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
